Cargando…
Ribonucleotide Reductase Inhibitors: A New Look at an Old Target for Radiosensitization
Ribonucleotide reductase (RR), the rate limiting enzyme in the synthesis and repair of DNA, has been studied as a target for inhibition in the treatment of cancer for many years. While some researchers have focused on RR inhibitors as chemotherapeutic agents, particularly in hematologic malignancies...
Autores principales: | Chapman, Tobias R., Kinsella, Timothy J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356024/ https://www.ncbi.nlm.nih.gov/pubmed/22655252 http://dx.doi.org/10.3389/fonc.2011.00056 |
Ejemplares similares
-
Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present
por: Huff, Sarah E., et al.
Publicado: (2022) -
The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML
por: Cook, Guerry J., et al.
Publicado: (2014) -
Convergent allostery in ribonucleotide reductase
por: Thomas, William C., et al.
Publicado: (2019) -
The periodic table of ribonucleotide reductases
por: Ruskoski, Terry B., et al.
Publicado: (2021) -
Ribonucleotide reductase, a novel drug target for gonorrhea
por: Narasimhan, Jana, et al.
Publicado: (2022)